The practice inflated costs for consumers and insurers on key treatments for cancer, multiple sclerosis, HIV, organ transplants, and other conditions and procedures, the FTC said. The report demonstrates how pharmacy benefit managers influence every aspect of the pharmaceutical supply chain,